Baxter CDMO BioPharma Solutions names Franco Negron as CEO ahead of proposed sale

Bax­ter’s CD­MO arm, Bio­Phar­ma So­lu­tions, has an­nounced a new CEO will take the reins fol­low­ing its pro­posed sale to pri­vate eq­ui­ty com­pa­ny Ad­vent In­ter­na­tion­al and in­vest­ment out­fit War­burg Pin­cus for $4 bil­lion.

Ad­vent and War­bug picked No­var­tis vet­er­an Fran­co Ne­gron to lead the charge. Ne­gron has more than 30 years of ex­pe­ri­ence in the man­u­fac­tur­ing and phar­ma in­dus­try, and pre­vi­ous­ly served as CEO of the med­ical tech­nol­o­gy com­pa­ny Api­Ject and held lead­er­ship po­si­tions at con­tract man­u­fac­tur­er Patheon be­fore Ther­mo Fish­er ac­quired it in 2017. He al­so served at Valeant Phar­ma­ceu­ti­cals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.